Day: May 8, 2025

Net revenue in Q1 2025 increased by 28% year-over-year, 33% year-over-year net revenue growth on a constant currency basis PEACE NATURALS® retained its position as the number one cannabis brand in Israel1 Industry-leading balance sheet with $838 million in total cash and cash equivalents and short-term investments TORONTO, May 08, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2025 first quarter business results. “2025 is shaping up to be a transformative year for Cronos as we execute our strategic priorities to drive revenue growth, expand margins, and maintain disciplined cost management. While strong demand for our flower products has recently outpaced supply, we are confident that our Cronos GrowCo expansion, on track for completion in the second quarter...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025 Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projections Presenting additional data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002 in patients with HAE at EAACI Congress in June 2025 Expect to present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study of nex-z in the second half of 2025 Ended the first quarter with approximately $707.1 million in cash, cash equivalents and marketable securities; Expected...

NORCROSS, Ga., May 08, 2025 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended March 31, 2025. “Overall revenue of $16.7 million in the first quarter exceeded our expectations, reflecting year-over-year total revenue growth of 28%, primarily driven by higher professional services rates from our largest customer and continued growth from our other customers,” said Leland Strange, CEO of CoreCard. “We continue to see encouraging results from the ongoing investment in our platform and processing capabilities, and we continue to onboard new customers that value the features and functionality offered...

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell engager programs utilizing Xilio’s novel ATACR and SEECR formats, with first development candidates anticipated in second half of 2025 WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2025. “In the first quarter, we presented encouraging initial Phase 2 data for vilastobart, our tumor-activated...

Financial HighlightsQ2 Performance Driven by Revenue Growth Across Recorded Music and Music Publishing Cost Savings Plans on Track, With Reinvestment Initiatives Accelerating Year-to-Date Operating Cash Flow and Free Cash Flow Increased by 53% and 59%, RespectivelyFor the three months ended March 31, 2025Total revenue decreased 1%, or increased 1% in constant currency Net income decreased 63% to $36 million versus $96 million in the prior-year quarter Operating income increased 41% to $168 million versus $119 million in the prior-year quarter Adjusted OIBDA decreased 3% to $303 million, versus $312 million in the prior-year quarter, or 1% in constant currency Cash provided by operating activities increased to $69 million from cash used in operating activities of $31 million in the prior-year quarterNEW YORK, May 08, 2025 (GLOBE...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement in TTR, substantial improvements in muscle health; NDA submission for accelerated approval with monthly dosing planned for 2026 IND submission expected...

First Quarter Revenue of $60.4 million, driven primarily by record Interactive revenue, up 49% year-over-year First Quarter Net Loss of $0.1 million and Adjusted Net Income of $3.8 million First Quarter Adjusted EBITDA of $18.4 million, up 19% from last year driven by record Interactive Adjusted EBITDA, up 75% year-over-year Entered into commitment letter for new £270 million senior secured debt to refinance existing debtNEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, today reported financial results for the three-month period ended March 31, 2025. “We are pleased to report a strong start to 2025, reflecting the continued momentum across our diversified business segments,” said Lorne...

MONTREAL, May 08, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1-25 Highlights Financial resultsRevenues were $88,076, an increase of $1,472 or 2% over the same period in prior year. The increase was driven by the growth of our key promoted products including our recent launches, partly offset by declines of our mature products and the depreciation of select LATAM currencies. Gross margin was $34,866 or 40% of revenues compared to $41,699 or 48% of revenues in the same period in prior year. The decrease was...

TORONTO, May 08, 2025 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK; TSX:STCK.WT.A) today announced its financial results for the quarter ended March 31, 2025. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Company Commentary:As at March 31, 2025, Book Value per Share (BVpS) of the Company was $12.06, compared with $12.29 as at December 31, 2024. Stack Capital had its first portfolio investment, CoreWeave (an AI hyper-scaler) go public on March 28, 2025, an exciting milestone for both the Company and CoreWeave. During the quarter, and prior to the IPO, Stack invested an additional US$2.2 million into CoreWeave. As of March 31, 2025, the Company wrote down its investment in CoreWeave by US$2.4 million to reflect its closing price of US$37.08. Since then,...

BALTIMORE, May 08, 2025 (GLOBE NEWSWIRE) — MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for first quarter 2025.(1) First Quarter 2025 Highlights(1)Paid Subscribers were 473 thousand as of March 31, 2025 compared with 683 thousand as of March 31, 2024(3) Total Net Revenue was $83.5 million in 1Q 2025 compared with $109.0 million in 1Q 2024(2) Total Billings was $70.5 million in 1Q 2025 compared with $55.4 million in 4Q 2024 and $77.2 million in 1Q 2024 – excluding the 1Q 2024 Billings of Legacy Research, 1Q 2024 Billings were $61.4 million Net Income was $16.8 million in 1Q 2025 compared with $22.7 million in 1Q 2024 Cash...